期刊
CANCER LETTERS
卷 280, 期 2, 页码 177-183出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2009.03.016
关键词
Cancer; Clinical; HDAC; Inhibitor; Biomarker
类别
资金
- Medical Research Council [G9400953, G0500905] Funding Source: Medline
- Medical Research Council [G0500905, G9400953] Funding Source: researchfish
- MRC [G9400953, G0500905] Funding Source: UKRI
Post-translational modifications of histone and non-histone proteins by acetylation are known to play a key role in tumourigenesis. Pharmacological manipulation of acetylation has been possible with the identification of small molecule inhibitors of histone deacetylases (HDAC), the enzymes responsible for deacetylating lysine residues. An explosion of drug discovery efforts in recent years has led to the development of an extensive group of HDAC inhibitors, many of which have been shown pre-clinically to have potent antitumour activity. Clinical trials using these agents are now underway, with Vorinostat (suberoylanilide hydroxamic acid) having been approved by the FDA for treating cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent or recurrent disease. This review discusses how biomarkers are being identified and used to expand our knowledge of the mechanisms by which HDAC inhibitors exhibit their anti-cancer effects. In the longer term, biomarkers will provide a means towards achieving patient stratification in turnout types that will respond favourably to HDAC inhibitors. Crown Copyright (C) 2009 Published by Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据